Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could pr

Trial Details

NCT ID

NCT05111574

Phase

PHASE2

Sponsor

National Cancer Institute (NCI)

Status

RECRUITING

Cancer Type

Mucosal Melanoma Melanoma

Interventions

Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography Test
Magnetic Resonance Imaging

Locations (sample)

Auburn, California, United States|38.89657,-121.07689
Palo Alto, California, United States|37.44188,-122.14302
Englewood, Colorado, United States|39.64777,-104.98776
Aventura, Florida, United States|25.95648,-80.13921
Deerfield Beach, Florida, United States|26.31841,-80.09977

Key Eligibility Criteria

STEP 0 INCLUSION CRITERIA
Histologically proven mucosal melanoma by local pathology
Central PD-L1 tumor tissue submission
STEP 1 INCLUSION CRITERIA

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Mucosal Melanoma Melanoma Trials on Trialify →